



Editor's Note: This letter was published on January 30, 2020, at NEJM.org.

CORRESPONDENCE

Transmission of 2019-nCoV Infection from an Asymptomatic Contact in Germany

March 5, 2020

N Engl J Med 2020; 382:970-971 DOI: 10.1056/NEJMc2001468

Metrics

Chinese Translation 中文翻译


2115 Citing Articles

TO THE EDITOR:

The novel coronavirus (2019-nCoV) from Wuhan is currently causing concern in the medical community as the virus is spreading around the world. Since identification of the virus in late December 2019, the number of cases from China that have been imported into other countries is on the rise, and the epidemiologic picture is changing on a daily basis. We are reporting a case of 2019-nCoV infection acquired outside Asia in which transmission appears to have occurred during the incubation period in the index patient.

A 33-year-old otherwise healthy German businessman (Patient 1) became ill with a sore throat, chills, and myalgias on January 24, 2020. The following day, a fever of 39.1°C (102.4°F) developed, along with a productive cough. By the evening of the next day, he started feeling better and went back to work on January 27.

Figure 1.



Timeline of Exposure to Index Patient with Asymptomatic 2019-CoV Infection in Germany.

Before the onset of symptoms, he had attended meetings with a Chinese business partner at his company near Munich on January 20 and 21. The business partner, a Shanghai resident, had visited Germany between January 19 and 22. During her stay, she had been well with no signs or symptoms of infection but had become ill on her flight back to China, where she tested positive for 2019-nCoV on January 26 (index patient in **Figure 1**) (see **Supplementary Appendix**, available at NEJM.org, for details on the timeline of symptom development leading to hospitalization).

On January 27, she informed the company about her illness. Contact tracing was started, and the above-mentioned colleague was sent to the Division of Infectious Diseases and Tropical Medicine in Munich for further assessment. At presentation, he was afebrile and well. He reported no previous or chronic illnesses and had no history of foreign travel within 14 days before the onset of symptoms. Two nasopharyngeal swabs and one sputum sample were obtained and were found to be positive for 2019-nCoV on quantitative reverse-transcriptase–polymerase-chain-reaction (qRT-PCR) assay. Follow-up qRT-PCR assay revealed a high viral load of 108 copies per milliliter in his sputum during the following days, with the last available result on January 29.

On January 28, three additional employees at the company tested positive for 2019-nCoV (Patients 2 through 4 in **Figure 1**). Of these patients, only Patient 2 had contact with the index patient; the other two patients had contact only with Patient 1. In accordance with the health authorities, all the patients with confirmed 2019-nCoV infection were admitted to a Munich infectious diseases unit for clinical monitoring and isolation. So far, none of the four confirmed patients show signs of severe clinical illness.

This case of 2019-nCoV infection was diagnosed in Germany and transmitted outside Asia. However, it is notable that the infection appears to have been transmitted during the incubation period of the index patient, in whom the illness was brief and nonspecific.³

The fact that asymptomatic persons are potential sources of 2019-nCoV infection may warrant a reassessment of transmission dynamics of the current outbreak. In this context, the detection of 2019-nCoV and a high sputum viral load in a convalescent patient (Patient 1) arouse concern about prolonged shedding of 2019-nCoV after recovery. Yet, the viability of 2019-nCoV detected on qRT-PCR in this patient remains to be proved by means of viral culture.

Despite these concerns, all four patients who were seen in Munich have had mild cases and were hospitalized primarily for public health purposes. Since hospital capacities are limited — in particular, given the concurrent peak of the influenza season in the northern hemisphere — research is needed to determine whether such patients can be treated with appropriate guidance and oversight outside the hospital.

Camilla Rothe, M.D. Mirjam Schunk, M.D. Peter Sothmann, M.D. Gisela Bretzel, M.D.

Guenter Froeschl, M.D.

Claudia Wallrauch, M.D.

Thorbjörn Zimmer, M.D.

Verena Thiel, M.D.

Christian Janke, M.D.

University Hospital LMU Munich, Munich, Germany

rothe@lrz.uni-muenchen.de

Wolfgang Guggemos, M.D.

Michael Seilmaier, M.D.

Klinikum München-Schwabing, Munich, Germany

Christian Drosten, M.D.

Charité Universitätsmedizin Berlin, Berlin, Germany

Patrick Vollmar, M.D.

Katrin Zwirglmaier, Ph.D.

Sabine Zange, M.D.

Roman Wölfel, M.D.

Bundeswehr Institute of Microbiology, Munich, Germany

Michael Hoelscher, M.D., Ph.D.

University Hospital LMU Munich, Munich, Germany

Disclosure forms provided by the authors are available with the full text of this letter at NEJM.org.

This letter was published on January 30, 2020, and updated on February 6, 2020, at NEJM.org.



Supplementary Material

Supplementary Appendix PDF 122KB

Disclosure Forms PDF 407KB

Citing Articles (2115)

Only the 1000 most recent citing articles are listed here.

EDITORIAL

Close Citing Articles

More about INFECTIOUS DISEASE VIRAL INFECTIONS GLOBAL HEALTH DIAGNOSTICS

More from the week of March 5, 2020



ED

Tri

E-Cigarette Use in Illinois and Wisconsin — Final Report Vaping-Induced Acute Lung Injury

D.C. Christiani G.